David P. Ryan
Impact in
- Oncology top 0.05%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
- Oncology 164
- Pancreatic and Hepatic Oncology Research 71
- Colorectal Cancer Treatments and Studies 42
- Colorectal Cancer Surgical Treatments 29
-
- Cancer Genomics and Diagnostics 27
- Co-authors
- Theodore Sunki Hong (79 shared papers)Nabeel Bardeesy (3 shared papers)Jeffrey William Clark (96 shared papers)Charles S. Fuchs (41 shared papers)Lawrence Scott Blaszkowsky (65 shared papers)Andrew Xiuxuan Zhu (52 shared papers)Matthew H. Kulke (25 shared papers)Peter Enzinger (24 shared papers)
- Journals
- The Oncologist (32 papers)Journal of Clinical Oncology (26 papers)Clinical Cancer Research (24 papers)Cancer (23 papers)International Journal of Radiation Oncology*Biology*Physics (20 papers)
- Partner nations
- United StatesIrelandCanada
In The Last Decade
David P. Ryan
360 papers receiving 27.2k citations
David P. Ryan's Hit Papers
Peers
Comparison fields: 5 of 189
- Oncology 13.3k
- Cancer Research 4.9k
- Hepatology 2.0k
- Pulmonary and Respiratory Medicine 4.3k
- Surgery 4.3k
Countries citing papers authored by David P. Ryan
This map shows the geographic impact of David P. Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David P. Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David P. Ryan more than expected).
Fields of papers citing papers by David P. Ryan
This network shows the impact of papers produced by David P. Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David P. Ryan. The network helps show where David P. Ryan may publish in the future.
Co-authors
The 25 scholars most cited alongside David P. Ryan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 378 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pancreatic Adenocarcinoma Hit paper breakdown → | 2014 | 1829 |
| 2 | Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Hit paper breakdown → | 2004 | 1658 |
| 3 | Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer Hit paper breakdown → | 2014 | 679 |
| 4 | Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial Hit paper breakdown → | 2017 | 650 |
| 5 | Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping Hit paper breakdown → | 2011 | 631 |
| 6 | Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors Hit paper breakdown → | 2008 | 509 |
| 7 | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study Hit paper breakdown → | 2020 | 469 |
| 8 | Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma Hit paper breakdown → | 2016 | 464 |
| 9 | Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer Hit paper breakdown → | 2019 | 444 |
| 10 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer Hit paper breakdown → | 2015 | 438 |
| 11 | Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma Hit paper breakdown → | 2018 | 438 |
| 12 | 2006 | 426 | |
| 13 | 2012 | 424 | |
| 14 | Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers Hit paper breakdown → | 2019 | 403 |
| 15 | 2009 | 390 | |
| 16 | 2000 | 368 | |
| 17 | Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Hit paper breakdown → | 2015 | 360 |
| 18 | 2005 | 359 | |
| 19 | 2012 | 358 | |
| 20 | 2014 | 353 |
About David P. Ryan
David P. Ryan is a scholar working on Oncology, Cancer Research, Hepatology, Surgery and Agronomy and Crop Science, having authored 378 papers that have together received 28.0k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (71 papers), Colorectal Cancer Treatments and Studies (42 papers), Colorectal Cancer Surgical Treatments (29 papers), Cancer Genomics and Diagnostics (27 papers), Colorectal and Anal Carcinomas (27 papers), Reproductive Physiology in Livestock (23 papers), Hepatocellular Carcinoma Treatment and Prognosis (22 papers) and Genetic and phenotypic traits in livestock (18 papers). The work is most often cited by research in Oncology (13.3k citations), Cancer Research (4.9k citations), Hepatology (2.0k citations), Pulmonary and Respiratory Medicine (4.3k citations) and Surgery (4.3k citations). David P. Ryan has collaborated with scholars based in United States, Ireland and Canada. Frequent co-authors include Theodore Sunki Hong, Nabeel Bardeesy, Jeffrey William Clark, Charles S. Fuchs, Lawrence Scott Blaszkowsky, Andrew Xiuxuan Zhu, Matthew H. Kulke, Peter Enzinger, Eunice Lee Kwak and Robert J. Mayer. Their work appears in journals such as The Oncologist, Journal of Clinical Oncology, Clinical Cancer Research, Cancer and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.